Health Care & Life Sciences » Pharmaceuticals | Zhejiang Starry Pharmaceutical Co. Ltd.

Zhejiang Starry Pharmaceutical Co. Ltd. A | Balance Sheet

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
54
49
126
233
208
187
Total Accounts Receivable
147
106
170
169
283
343
Inventories
166
197
210
299
287
429
Other Current Assets
6
17
4
3
8
7
Total Current Assets
373
369
511
703
785
966
Net Property, Plant & Equipment
531
667
851
1,051
1,086
1,326
Total Investments and Advances
3
3
3
21
18
18
Intangible Assets
96
106
105
103
110
737
Other Assets
6
4
5
10
10
13
Total Assets
1,009
1,150
1,478
1,894
2,013
3,067
ST Debt & Current Portion LT Debt
397
347
534
548
535
Accounts Payable
59
87
37
62
63
Income Tax Payable
2
10
7
8
5
Other Current Liabilities
28
23
67
31
30
Total Current Liabilities
486
468
645
649
632
Long-Term Debt
110
227
354
387
490
Deferred Taxes
1
1
3
4
4
Total Liabilities
596
694
999
1,036
1,122
Common Equity (Total)
380
421
441
810
857
Total Shareholders' Equity
380
421
441
810
857
Total Equity
386
432
458
827
872
Liabilities & Shareholders' Equity
1,009
1,150
1,478
1,894
2,013
Accumulated Minority Interest
6
11
17
17
15
Non-Equity Reserves
27
24
22
30
19

About Zhejiang Starry Pharmaceutical Co.

View Profile
Address
9 Fengxi West Road
Taizhou Zhejiang 317306
China
Employees -
Website http://www.starrypharm.com
Updated 07/08/2019
Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of active ingredient and intermediate X-CT non-ionic contrast agent and fluoroquinolones series. Its products include fluorine quinoline derivatives, carbapenem, iohexol, ioversol, iopamidol, iopromide, iodixanol, levofloxacin, levofloxacin hydrochloride, levofloxacin acid ester, levofloxacin acid, pazufloxacin, pazufloxacin mesylate, meropenem, faropenem sodium, iomeprol, and gadobenate dimeglumine. The company was founded on September 15, 1997 and is headquartered in Taizhou, China.